NEW YORK–(BUSINESS WIRE)– #BetterOutcomes–AccurKardia, Inc., an ECG analytics software company focused on establishing ECG as a broad biomarker, today announced that it has been granted US Patent No. 12,620,488 for the company’s proprietary machine-learning-based system for identifying cardiac amyloidosis from a standard, routinely performed 12-lead ECG. Cardiac amyloidosis is a serious, often fatal heart disease in which abnormal proteins build up in heart tissue, causing the heart muscle to stiffen and even
See the full post here as oringinally posted on this site.
